ABSTRACT
Glypican-3 (GPC3) is an oncofetal protein anchored on the plasma membrane and highly expressed in hepatocellular carcinoma (HCC).GPC3 could he used as a biomarker for the diagnosis of HCC and the serum levels of GPC3 in liver cancer patients has a significant role for their prognosis.Moreover, GPC3 in HCC cells is immunoreactive, rendering it a suitable target for the treatment of HCC.Nowadays, several clinical trials targeting GPC3 for HCC therapy have already been conducted: new anti- GPC3 antibodies are generated; the clinical trials about its combination administration with other targeted medicines are being in progress; (tP(3-targeted TRAB, GPC3 vaccines and GPC3-based chimeric antigen receptor T-cells (CAR-T) therapy are under investigation.In this review, we briefly discuss the structure of GPC3, its role in HCC pathogenesis and summarize the recent development in the clinical application of GPC3.We firmly believe that GPC3 would be a promising target for HCC therapy.And further studies focusing on GPC3 should provide us more solid evidence.
ABSTRACT
Glypican-3 (GPC3) is a key member of Glypican family and plays an important role in the development, angiogenesis and metastasis of hepatocellular carcinoma (HCC). Most HCC overexpresses GPC3, but GPC3 is hardly detected in normal adult liver and benign liver lesions, so it is regarded as a highly specific diagnostic marker and an ideal therapeutic target for HCC. In this study, we cloned the heavy and light chain variable region gene from the monoclonal antibody targeted to GPC3 screened in the previous stage, and linked it with a segment of flexible peptide (Linker) to obtain the single chain antibody against GPC3. The single chain antibody gene was cloned into vector for prokaryotic expression and purified to obtain high purity protein. Detection shows that the single-chain antibody produced by us has the same binding activity with the full-length antibody, and can accurately target the tumor site of Huh7 tumor-bearing model mice after coupling Cy5.5 fluorescence, suggesting that the single-chain antibody has the potential to realize multi-directional liver cancer precise surgical navigation under the guidance of a probe.
Subject(s)
Animals , Mice , Antibodies, Monoclonal , Carcinoma, Hepatocellular/genetics , Glypicans/genetics , Liver Neoplasms/diagnosisABSTRACT
Objective: To investigate the clinicopathological features and molecular phenotypes of gastric cancer with enteroblastic dif-ferentiation (GCED). Methods: A retrospective analysis of 337 patients with gastric adenocarcinoma diagnosed by the pathology de-partment of the First Affiliated Hospital of Zhejiang University in March 2013-2017 was conducted. Of them, 8 patients were diag-nosed with gastric carcinoma with intestinal blastocyte differentiation. All the patients were elderly, including 6 men and 2 women. The onset age was 68-83 years (mean 76.6 years). Two cases had serum AFP≥200 μg/L before treatment. According to the histopatho-logical morphology, the immunophenotype was analyzed by immunohistochemistry, the SALL4 gene was detected using reverse tran-scription-polymerase chain reaction (RT-PCR), and the relevant literature was reviewed. Results: Microscopically, all cases had primi-tive enteroid structures, consisting of cubic or columnar cells with clear cytoplasm, and immunohistochemical staining showed positivi-ty for either AFP and GPC3 or SALL4. The expression of SALL4 mRNA was significantly increased by RT-PCR. Follow-up from 1 to 5 years showed that 5 patients had liver and other organ metastases, 2 patients died, and 1 patient survived without a tumor. Conclusions:GCED is a rare invasive gastric adenocarcinoma with a worse prognosis than that of normal intestinal adenocarcinoma. The treatment of general intestinal adenocarcinoma has little effect. There are some characteristic changes in histology. It would be helpful for diag-nosis and differential diagnosis if clinicians are familiar with the tumor spectrum and genetic characteristics. Target therapy for an origi-nal marker, such as SALL4, has a bright future.
ABSTRACT
@#【Objective】To explore the correlation between the expression levels of copper chaperone for superoxide dismutase（CCS）and the malignancy related biomarkers in hepatocellular carcinoma（HCC）.【Methods】From January to December 2018，we obtained fresh samples of surgically dissected HCC paired with para-carcinoma normal tissues from 10 HCC patients and collected their clinical and pathological data. Western blotting（WB）was performed to examine the expression of CCS in HCC tissues and adjacent noncancerous tissues. Immunohistochemical staining（IHC）was employed to detect the expression of Ki67，CD34，vimentin and glypican-3（GPC3）. The correlation between the expression levels of CCS and biomarkers was analyzed by using Wilcoxon rank sum test. The association between CCS expression and clinical pathological characteristics of HCC patients was investigated by using Fisher′s exact probability test.【Results】In 7 of the 10 HCC cases，the expression level of CCS in HCC tissue samples was lower than that in adjacent noncancerous tissues，and in other 3 HCC cases，CCS expression higher. In the group with low CCS expression，compared with those in the group with high CCS expression，the expression levels of Ki67，vimentin and GPC3 were higher （Z=- 2.400，P=0.016；Z=- 2.423，P=0.015；Z=- 2.400，P=0.016），while the expression level of CD34 lower（Z=- 2.423，P=0.015）. There was no statistically significant difference in clinical and pathological variables including gender ，age ，hepatitis B virus infection，liver cirrhosis，preoperative serum AFP level，tumor size，Edmondson-Steiner grade and microvascular invasion between two groups with high and low CCS expression.【Conclusions】The results revealed that in most of HCC patients，the expression level of CCS in HCC tissues was lower than that in adjacent noncancerous tissues. Additionally ， higher expression levels of Ki67，vimentin and GPC3 in HCC tissues with low CCS expression indicated that low expression level of CCS correlated with malignant biological behaviors such as HCC proliferation ，invasion and metastasis. The mechanism that the expression level of CD34 appeared lower in HCC tissues with low CCS expression，however，needs further study. These findings suggest that compared with that in normal liver tissues，CCS expression is decreased in a majority of the cases，and it may serve as a promising therapeutic and prognostic biomarker for HCC.
ABSTRACT
Objective To prepare a targeted ultrasound micro bubble,which carried the HSV-TK gene,and investigate the in vitro target searching ability of the micro bubbles and inhibitory effect on the proliferation of HepG2 cells.Methods Ultrasonic micro bubbles were prepared by mechanical vibration method,construction of targeted HSV-TK ultrasound micro bubbles by biotin affinity bridge construction.To detect the general characteristics of ultrasound micro bubbles,and to test its effect on the proliferation of HepG2 cells in vitro.Results HSV-TK targeted ultrasound microbubbles more gathered on the surface of HepG2 cells,through detection of PCNA and MTT,it was found that the proliferation of gene targeting microbubble group was obviously decreased,cell apoptosis increased significantly,Cells invade experiments showed that the number of cells in genetic microbubble group (22.18 ± 2.01) decreased significantly compared with the control group and the nontargeted group,can effectively inhibit the proliferation and invasive ability of HepG2 cells.Conclusion Targeted ultrasound microbubble carrying target gene have better inhibitory effect on HepG2 cells in vitro.
ABSTRACT
OBJECTIVES@#To build GPC3 gene short hairpin interference RNA (shRNA) slow virus vector, observe expression of Huh-7 GPC3 gene in human liver cell line proliferation apoptosis and the effect of GPC3 gene influencing on liver cancer cell growth, and provide theoretical basis for gene therapy of liver cancer.@*METHODS@#Hepatocellular carcinoma cell line Huh-7 was transfected by a RNA interference technique. GPC3 gene expression in a variety of liver cancer cell lines was detected by fluorescence quantitative PCR. Targeted GPC3 gene sequences of small interfering RNA (siRNA) PGC-shRNA-GPC3 were restructured. Stable expression cell lines of siRNA were screened and established with the help of liposomes (lipofectamine(TM2000)) as carrier transfection of human liver cell lines. In order to validate siRNA interference efficiency, GPC3 siRNA mRNA expression was detected after transfection by using RT-PCR and Western blot. The absorbance value of the cells of blank group, untransfection group and transfection group, the cell cycle and cell apoptosis were calculated, and effects of GPC3 gene on Huh-7 cell proliferation and apoptosis were observed.@*RESULTS@#In the liver cancer cell lines Huh-7, GPC3 gene showed high expression. PGC-shRNA-GPC3 recombinant plasmid was constructed successfully via sequencing validation. Stable recombinant plasmid transfected into liver cancer cell lines Huh-7 can obviously inhibit GPC3 mRNA expression level.@*CONCLUSIONS@#The targeted GPC3 siRNA can effectively inhibit the expression of GPC3.
ABSTRACT
Objective To prepare monoclonal antibody specifically against carcinoembryonic antigen glypican-3 (GPC3) and its preliminary application. Methods GPC3 was cloned with PCR to pET16b vector and expressed in E. co-liBL21. Spleen cells were obtained from Balb/c mice embedding immunized with purified antigen intraperitoneally, and fused with Sp2/0 cells. Hybridoma cells were screened by indirect ELISA, and identified by Western blot assay using puri-fied protein after the cell fusion. The indirect immunofluorescence method was used to detect the GPC3 expression in HepG2 cell line. Results The prokaryotic expression vector of GPC3 was successfully constructed, and GPC3 was stably expressed in E. coliBL21. A mouse hybridoma cell line secreting monoclonal antibody to GPC3 was obtained. Western blot analysis showed that monoclonal antibody specifically recognized recombinant protein. Monoclonal antibody could be used to detect GPC3 protein expression in HepG2 cell line by indirect immunofluorescence. Conclusion The monoclonal antibody against GPC3 was successfully obtained.
ABSTRACT
Objective To research the effect of mir-520c-3p targeted GPC3 to the hepatocellular carcinoma Huh-7 cell proliferation,migration,and the influence of the attack ability and find new theoretical basis for liver hepatocellular carcinoma clinical treatment.Methods The cells were divided into three groups:not transfection of mir-520c-3p group (cell group),negative control group (Nc group),and transfection of mir-520c-3p group (treat ment group).Then used fluorescence quantitative PCR and Western Blot to detect GPC3mRNA gene and protein expression quantity.Cell proliferation of change was detected by the EDU.Made use of Transwell to detect cell invasion and migration ability of the change.Results Fluorescence quantitative PCR results showed that Cell group,NC group and treatment group were 1.13 ± 0.23,1.28 ± 0.15 and 1.05 ± 0.19 (P ＞ 0.05),mir-520-3p could not reduce the GPC3mRNA; but Western Blot detection results showed that GPC3 protein expression level reduce significantly after transfection mir-520c-3p,Cell,NC and treatment group were 2.16 ± 0.08,1.99 ± 0.04 and 0.499 ± 0.05 (P ＜ 0.01).The EDU detection results showed that hepatocellular carcinoma Huh-7 cell proliferation ability obviously inhibited after transfection mir-520c-3p,Cell group,NC group and treatment group were (90.12 ± 1.93) ％,(91.02 ± 0.35) ％ and (77.73 ± 5.88) ％ (P ＜ 0.05),and Transwell test found that hepatocellular carcinoma Huh-7cell invasion abilities were restrained,Cell group,NC group and treatment group were 0.071 ±0.008,0.105 ±0.001 and 0.048 ± 0.002 (P ＜ 0.05),in the same the cells' migration abilities were reduced,Cell group,NC group and treatment group were 0.546 ± 0.010,0.328 ± 0.002 and 0.151 ± 0.002 (P ＜0.01).Conclusions Mir-520c-3p can target GPC3 so that affect hepatocellular carcinoma Huh-7 cell proliferation,invasion and migration abilities.
ABSTRACT
Objective: To construct a GPC3 green fluorescent protein eukaryotic expression vector pEGFP-N2-G-PC3, and analyze its effects on the growth promoting effect of growth factors (fibroblast growth factor-2, FGF2; insulin-like growth factor-2, IGF2; transforming growth factor-β1, TGF-β1; and bone morphogenetic protein-4,BMP4) in human hepatoma cell line GPC3-SK-Hep-1. Methods: A eukaryotic expression vector for GPC3 genes (pEGFP-N2-GPC3) was constructed by recombinant DNA technique and was transfected into SK-Hep-1 cells by Lipofectamine™ 2000; the cells stably expressing GPC3 were screened out by G418 (600 μg/ml). The mRNA expression of GPC3 was detected by RT-PCR method and the protein expression of GPC3 by Western blotting and fluorescence microscope. Effects of GPC3 gene on the growth promoting effects of the above growth factors were examined by MTT. Results: The recombinant plasmid was verified to be correctly constructed by restriction endonuclease analysis and DNA sequencing. The green fluorescence was detected in the transfected SK-Hep-1 cells under fluorescence microscope. RT-PCR and Western blotting both confirmed that GPC3 was successfully expressed in SK-Hep-1 cells. FGF2-induced cell proliferation was significantly decreased by GPC3 gene, whereas the growth promoting effects of IGF2, TGF-β1 and BMP4 were not altered by GPC3 gene. Conclusion: We have successfully obtained the synthetic GPC3 protein, which has the same amino acid sequence as that of human GPC3 protein. The eukaryotic expression vector pEGFP-N2-GPC3 has been correctly constructed and GPC3 protein has been successfully expressed in SK-Hep-1 cells. GPC3 may negatively modulate FGF2 signaling pathway.
ABSTRACT
Objective:To study the influence of GPC3 gene on the proliferation,adhesion and invasion of hepatoma cell line SK-Hep-1.Methods:SK-Hep-1 cells were transfected with pEGFP-N2-GPC3 using Lipofectamine2000.RT-PCR was used to examine the GPC3mRNA expression in GPC3-SK-Hep-1 cells.MTT assay was used to examine the proliferation and calculate the adhesion rate of SK-Hep-1 cells.Transwell system was used to assess the migration and invasion of the cells.Results:SK-Hep-1 cells were successfully transfected with pEGFP-N2-GPC palsmid.GPC3 mRNA was detected in SK-Hep-1 cells.Transfection with CPC3 significantly suppressed the growth of SK-Hep-1 cells(P
ABSTRACT
Objective:To study the clinical significance of serum glypican-3 in patients with hepatocellar carcinoma who underwent interventional therapy.Methods:Serum levls of glypican-3 were detected with ELISA in patients with hepatocellar carcinoma,cirrhosis and normal people.Results:Serum levels of glypican-3 in patients with hepatocellar carcinoma(52 cases)were significantly higher than those with cirrhosis(16 cases)or healthy group(30 cases)(P